AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:21 2024-07-17 EDT			5-day change	1st Jan Change
12,244 ^GBX	+1.19%		+2.51%	+15.51%

07-17	AstraZeneca's Capivasertib Gets UK Marketing Authorization for Advanced Breast Cancer Treatment	MT
07-17	EU court criticizes Commission over handling of COVID vaccine contracts	RE

Astrazeneca Says In Conversation With Eu's Von Der Leyen, Ceo Stressed Importance Of Working In Partnership, How Co Is Doing Everything It Can To Bring Vaccine To Millions Of Europeans As Soon As Possible

January 25, 2021 at 07:22 am

ASTRAZENECA SAYS IN CONVERSATION WITH EU'S VON DER LEYEN, CEO STRESSED IMPORTANCE OF WORKING IN PARTNERSHIP, HOW CO IS DOING EVERYTHING IT CAN TO BRING VACCINE TO MILLIONS OF EUROPEANS AS SOON AS POSSIBLE

Latest news about AstraZeneca PLC

AstraZeneca's Capivasertib Gets UK Marketing Authorization for Advanced Breast Cancer Treatment	07-17	MT
EU court criticizes Commission over handling of COVID vaccine contracts	07-17	RE
Global markets live: Airbus, Burberry, AT&T, Boeing, Vinfast...	07-15
AstraZeneca: acquisition of Amolyt Pharma finalized	07-15	CF
AstraZeneca Closes $1.05 Billion Amolyt Pharma Acquisition	07-15	MT
AstraZeneca PLC completed the acquisition of Amolyt Pharma SAS for $1.05 billion.	07-14	CI
Instil Bio Shares Surge Following Rental Agreement with AstraZeneca	07-12	DJ
Sector Update: Health Care Stocks Mixed Premarket Friday	07-12	MT
Instil Bio Signs Lease With AstraZeneca Pharmaceuticals at California Facility; Shares Rise After Hours	07-11	MT
ASTRAZENECA : Deutsche Bank reiterates its Neutral rating	07-10	ZD
Barclays raises Kerry, cuts Hunting, Wood Group	07-10	AN
ASTRAZENECA : JP Morgan reaffirms its Buy rating	07-10	ZD
AstraZeneca's Tagrisso Approved by EU as First-Line Treatment for Non-Small Cell Lung Cancer	07-05	MT
AstraZeneca: cancer treatment approved by the EU	07-05	CF
AstraZeneca drug Tagrisso gets EU approval for cancer form	07-05	AN
EU Approves AstraZeneca's Tagrisso Combo as Non-small Cell Lung Cancer Treatment	07-05	MT
ASTRAZENECA : Goldman Sachs maintains a Buy rating	07-04	ZD
ASTRAZENECA : Buy rating from Berenberg	07-03	ZD
Aptamer shares jump as inks agreement with AstraZeneca	07-03	AN
Aptamer Group plc Announces New Agreement with AstraZeneca to Evaluate the Optimer Fibrotic Liver Delivery Vehicles for the Targeted Delivery of SiRNA	07-03	CI
ASTRAZENECA : Jefferies reaffirms its Neutral rating	07-02	ZD
Deutsche Bank cuts Quilter, ups Polar Capital	07-02	AN
European Equities Close Higher in Monday Trading; Eurozone Manufacturing Contraction Widens in June	07-01	MT
UK Stocks Flat; Manufacturing Sector Remains in Expansion Zone	07-01	MT
AstraZeneca's Potential Covid-19 Prevention Drug Gets EU Accelerated Assessment	07-01	MT

Chart AstraZeneca PLC

Duration

Period

More charts

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

159.2 USD

Average target price

177.6 USD

Spread / Average Target

+11.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+15.51%	243B
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B
SANOFI	+2.52%	125B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Astrazeneca Says In Conversation With Eu's Von Der Leyen, Ceo Stressed Importance Of Working In Partnership, How Co Is Doing Everything It Can To Bring Vaccine To Millions Of Europeans As Soon As Possible

EPS Revisions